Research summaries for everyoneNot medical advice
AOD9604 research reference vial, Elevated Pharma

Research reference · Weight & Metabolism

AOD9604

AOD9604 is a modified fragment of the C-terminal end of human growth hormone, studied in mouse metabolic models and in early human obesity trials that did not lead to approval.

Published by Elevated Pharma ·

Weight & MetabolismPreclinical literature / FDA review

Identity

What is AOD9604?

A modified hGH fragment (residues 177–191 with an added tyrosine).

Research context

What has AOD9604 been studied for?

Published work includes mouse fat-metabolism studies, a rabbit joint model and doping-detection methods.

Evidence boundary

What does the research not show?

Mouse findings do not establish human effectiveness or safety.

U.S. status · November 7, 2026

Is AOD9604 FDA-approved?

Not FDA-approved. FDA has cited insufficient safety information for compounded AOD-9604.

Key studies

The main AOD9604 research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all 22 PubMed records for AOD9604 · Counts and selections checked November 7, 2026.

Reference identifiers

AOD9604 identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
AOD9604
Also indexed as
AOD-9604 / Modified growth hormone C-terminal fragment
Molecular formula
C78H123N23O23S2
Molecular mass
1815.1 g/mol
PubChem CID
71300630

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.